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Abstract
Background: Identification of the causative genes of retinitis pigmentosa (RP) is important for the clinical care of
patients with RP. However, a comprehensive genetic study has not been performed in Korean RP patients.
Moreover, the genetic heterogeneity found in sensorineural genetic disorders makes identification of pathogenic
mutations challenging. Therefore, high throughput genetic testing using massively parallel sequencing is needed.
Results: Sixty-two Korean patients with nonsyndromic RP (46 patients from 18 families and 16 simplex cases) who
consented to molecular genetic testing were recruited in this study and targeted exome sequencing was applied
on 53 RP-related genes. Causal variants were characterised by selecting exonic and splicing variants, selecting variants
with low allele frequency (below 1 %), and discarding the remaining variants with quality below 20. The variants were
additionally confirmed by an inheritance pattern and cosegregation test of the families, and the rest of the variants
were prioritised using in-silico prediction tools. Finally, causal variants were detected from 10 of 18 familial cases
(55.5 %) and 7 of 16 simplex cases (43.7 %) in total. Novel variants were detected in 13 of 20 (65 %) candidate variants.
Compound heterozygous variants were found in four of 7 simplex cases.
Conclusion: Panel-based targeted re-sequencing can be used as an effective molecular diagnostic tool for RP.
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Background
Retinitis pigmentosa (RP) is a group of hereditary retinal
diseases characterised by progressive loss of rod and
cone photoreceptor cells. It is the most common heredi-
tary retinal disease with a frequency of approximately 1
in 3000–4000 people, with an estimated total of 1.5
million people affected worldwide [1, 2]. Patients with
RP usually present with a loss of night vision and com-
plain of progressive constriction of the visual field.
Eventually, central vision is affected and worsens.
Clinical features such as age of onset and rate of
progression vary greatly between individuals.
The identification of causative genetic variants is ex-
pected to be the starting point of RP treatment. Genetic
counselling and gene therapy or other patient-specific
treatment options can be suggested based on genetic
background. In addition to treating the disease, molecu-
lar diagnosis is helpful for informing the differential
diagnosis. Hereditary retinal dystrophies have a slowly
progressive nature and complete clinical features may
not be present at the time of examination. Therefore,
many other hereditary retinal dystrophies may be con-
fused with RP at certain phases of disease progression.
However, the genetic heterogeneity of RP is a hurdle
for the easy application of molecular diagnosis. At the
time of September 2011, 53 genes and 7 mapped loci are
known to be associated with nonsyndromic RP [3]
(RetNet). These genes show considerable phenotypic
variability and multiple inherited retinal disease shares
certain causative genes with RP [4]. Because of this
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phenotypic heterogeneity and confusion between geno-
typic and phenotypic correlations, the clinical features of
individual patients provide few clues to narrow down the
list of candidate genes [2, 5]. Therefore, these genes and
loci should be screened simultaneously.
Massively parallel sequencing, also called next-generation
sequencing (NGS) is a recent technical breakthrough in
genetics [6, 7]. NGS-based high-throughput sequencing
even makes whole-genome sequencing available in a single
facility, which would have required tremendous cost and
time in the past. RP can be a good target for massively
parallel sequencing as an appropriate number of candidate
genes are known for RP. Therefore, this study attempts to
detect candidate variants in RP by applying a targeted
enrichment and re-sequencing strategy.
Results
Quality validation of sequencing
A total of 217.5 kbp of targeting and flanking regions
from 53 RP-related genes and 748 RP-related exons were
captured; 97.1 % of the 2.89 M reads obtained on aver-
age per individual were properly paired and mapped
(Additional file 1: Table S1). The average read depth was
146.2 ± 26.2, and 98.6 % and 96.5 % of the captured
target exons showed more than 1X and 10X coverage,
respectively (Additional file 1: Table S1).
Detection of variants in familial RP
Strong candidate variants of RP were identified in 10
families (Table 1). Among 18 families, 10 had an auto-
somal dominant, five had an autosomal recessive and
three had an X-linked inheritance pattern. Briefly, five
known pathogenic variants (c.421-1G > A in PRPF31,
p.P347L in RHO, p.A153V in KLHL7, p.Y178C in RHO,
p.R354X in PRPF31 were detected [8–13]. The known
variant, pC3416G in USH2A, was initially detected, but
the other variant, p.G4647R in the XF4 family under the
inheritance pattern of autosomal recessive (compound
heterozygote), was predicted as non-pathogenic. There-
fore, the XF4 family was excluded. The other five candi-
date variants in RP1, RP2 and TOPORS have not been
reported in dbSNP and were co-segregated in the family
members.
The 10 variants were comprised of four nonsynon-
ymous variants, four nonsense mutations, one frameshift
deletion, and one splicing variant. All the nonsense mu-
tations (p.Y485X in RP1, p.Q766X in RP1, p.R782X in
TOPORS, and p.R354X in PRPF31) were located at the
upstream exons (exon 4 of 4, exon 3 of 4, exon 2 of 3
and exon 10 of 16 respectively), which might lead to
nonsense-mediated decay of mRNA. A frameshift variant
(p. Ser187fs in RP2) was also located at the 5′ upstream
exon, and all the nonsense and frameshift variants were
classified as possible pathogenic variants (category II).
The clinical features were relatively severe in patients
having X-linked variants, F04 (p.C114R in RP2) and F12
(p.Ser187fs in RP2) (Additional file 1: Table S2). The
affected family members experienced early onset of
symptoms and presented with rapid progression. In the
F04 family, the proband (VI-1) was a 6-year-old male
whose visual acuity was 20/200 (OD) and 20/1000
(OS). The visual field was mildly constricted using a
Goldmann perimetry V4 target, and the rod responses
were extinguished and photopic responses were se-
verely decreased on the electroretinogram. The photo-
receptor inner segment and outer segment junction
was not detectable using OCT (optical coherence
tomography). The patient’s grandfather (II-1) had no
light perception in both eyes. Fundus examination and
OCT scan showed a severely degenerative retina. For
family F12, a possible pathogenic missense variant was
found in the X-linked RP2 gene. Hemizygous male
Table 1 Strong candidate variants in familiar cases
Family Inheritance Gene Genotype Chr Exon nucleotide amino acid Mutation Type Reference EVS In-house Class
F03 AD RP1 Hetero 8 4 c.1455 T > G p.Y485X nonsense novel - - II
F04 X-L RP2 Hemi X 2 c.340 T > C p.C114R nonsynonymous novel - - II
F06 AD RP1 Hetero 8 4 c.2296C > T p.Q766X nonsense novel - - II
F07 AD PRPF31 Hetero 19 6 c.421-1G > A splicing Xia et al. [11] - - I
F09 AD RHO Hetero 3 5 c.1040C > T p.P347L nonsynonymous rs29001566 - - I
F10 AD KLHL7 Hetero 7 5 c.458C > T p.A153V nonsynonymous rs137853113 - - I
F12 X-L RP2 Hemi X 2 c.560_561delGC p.Ser187fs Frameshift
deletion
novel - - II
F13 AD RHO Hetero 3 3 c.533A > G p.Y178C nonsynonymous rs104893776 - - I
XF1 AD TOPORS Hetero 9 2 c.2344C > T p.R782X nonsense novel - 0.0052083 II
XF3 AD PRPF31 Hetero 19 10 c.1060C > T p.R354X nonsense Sullivan et al.
[12]
- - I
Chr: chromosome; Homo: homozygous; Hetero: heterozygous; Hemi: hemizygous; AD: Autosomal Dominant; X-L X-linked
In-house: Korean normal reference consisting of 192 exomes
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patients (II-5, II-16 and III-2) showed poor visual acuity
at less than counting fingers. The retina was totally
degenerated such that the retina and choroid were not
distinguishable on OCT. Scoptopic and photopic elec-
troretinogram (ERG) were all extinguished. Female
patients of the F12 family (II-8, II-13, III-11 and III-20)
showed variable penetrance. Three of them (II-13, III-11
and III-20) were confirmed to have heterozygous variants.
Two female patients (III-11 and III-20) had mild periph-
eral pigmentary deposits and decreased rod and cone
amplitude on electroretinography. Two other female
patients (II-8 and II-13) showed complete expression of
RP. They had visual acuity limited to light perception in
both eyes, typical bony spicule pigment deposits, attenu-
ated retinal vessels. Scoptopic and photopic ERG ampli-
tude were also abolished.
F06 (p.Q766X in RP1) showed a milder phenotype.
In family F06, all patients experienced their first symp-
toms in their 30s. Two patients older than age 50 (II-3,
75 years old; III-2, 54 years old) had visual loss, while
the other patients (III-6, III-10 and III-13) had normal
vision. Patient III-6 and III-10 showed a normal mac-
ula on OCT and a mildly constricted visual field. The
clinical features of the patients and pedigrees are sum-
marised in Additional file 1: Table S2 and Figure S1.
Fundus photograph and OCT are presented in Additional
file 1: Figure S2.
Detection of variants in simplex RP
The possible pathogenic variants were also identified in
7 of 16 patients with simplex RP (43.7 %) (Table 2).
These patients denied a familial history of RP or related
hereditary disorders. The inheritance pattern of candi-
date genes was based on the sequencing results (Table 2).
Initially four known pathogenic variants, p.H278Y in
PDE6B, p.Y2935X and p.G2186E in EYS, and p.C3416G
in USH2A, were detected. [13–16]. However a possible
second variant in EYS (patient 435) and USH2A (patient
450) was not found, p.Y2935X (EYS) and p.C3416G
(USH2A) were not included in final results. Eight causal
candidate variants were newly identified. Overall, ten
possible pathogenic variants were detected. They were
comprised of six nonsynonymous, three nonsense, and
one frameshift insertion variants. Compound heterozy-
gous variants (in trans) were detected in five patients
(PDE6B in 436 and 445, EYS in 439 and 440, USH2A in
438). The same frameshift variant of EYS (p.S1653fs)
was identified in two unrelated patients with simplex RP
(439 and 440).
Regarding the clinical feature, patient 430 with the
PRPF31 mutation (p.E104K) showed a mild clinical
phenotype. Although he was 42 years old, his visual
acuity was 20/20 in both eyes, but a paracentral scotoma
was detected in the visual field test. The electroretino-
gram showed a small decrease only in rod response.
Most of the photoreceptor inner segment and outer
segment junction (5 mm in the horizontal scan) was
observed intact using an OCT macula scan (Additional
file 1: Table S3). Fundus photograph and OCT are pre-
sented in Additional file 1: Figure S2.
Discussion
In this study, targeted exome capture and massively par-
allel sequencing (MPS) was implemented for genetic
diagnosis of RP. Strong candidate variants were identi-
fied in 10 (55.5 %) of 18 families and 7 (43.7 %) of 16
sporadic patients. The overall detection rate was 50 %.
This method seems to be highly efficient and cost
Table 2 Strong candidate variants in sporadic cases
No Inheritance* Gene Genotype Chr Exon nucleotide amino acid Mutation Type Reference EVS In-house Class
430 AD PRPF31 Hetero 19 1 c.310G > A p.E104K nonsynonymous Novel - - II
432 AD PRPH2 Hetero 6 1 c.380A > G p.E127G nonsynonymous Novel - - II
436 AR PDE6B Compound hetero 4 8 c.832C > T p.H278Y nonsynonymous rs121918581 - - Ι
1 c.32G > A p.W11X nonsense Novel - - II
438 AR USH2A Compound hetero 1 42 c.8885 T > G p.L2962R nonsynonymous Novel - - II
18 c.4460G > A p.W1487X nonsense Novel - - II
439 AR EYS Compound hetero 6 8 c.1750G > T p.E584X nonsense Novel - - II
26 c.4958_4959insA p.S1653fs frameshift insertion Novel - - II
440 AR EYS Compound hetero 6 29 c.6557G > A p.G2186E nonsynonymous 10 Littink - - Ι
26 c.4958_4959insA p.S1653fs frameshift insertion Novel - - II
445 AR PDE6B Compound hetero 4 8 c.832C > T p.H278Y nonsynonymous rs121918581 - - I
8 c.767 T > A p.I256N nonsynonymous Novel - - II
*Inheritance is not inferred from pedigrees of the patients. These patients stated that there is no affected individual in their family tree other than indexed
patients. Inheritance pattern described the results suggested by sequencing data
In-house: Korean normal reference consisting of 192 exomes
Chr chromosome; AD Autosomal dominant; AR Autosomal recessive; X-L X-linked
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effective in comparison with PCR amplicon sequencing
and other conventional methods such as microarray ana-
lysis. It is certainly much higher than the 7–16 % detec-
tion rate of microarray genotyping [17–21]. A previous
genetic analysis of Korean RP patients using microarrays
revealed a causative mutation in 26 out of 336 patients
(2 %) [19]. The subjects of this microarray study were
different from the current study. Patients from the F09
and F13 families had also been screened for detection of
the RHO mutation by using direct sequencing in a previ-
ous study [22]. The current study analysed 53 target
genes and showed exactly the same results as the direct
sequencing of the RHO gene for these particular individ-
uals, thereby supporting the accuracy and efficiency of
the current strategy. The current results are also com-
parable with other RP genetic analysis using targeted
resequencing, in which the detection rate ranged from
36 to 82 % [23–28]. Unbiased sequencing, including
whole-genome or exome sequencing, can provide com-
prehensive genetic data that reveal novel causal genes
of RP such as NEK2, HK1 and MVK. However the
sequencing and data processing burden is still the
bottleneck for widespread use of unbiased sequencing.
Moreover, detection rates using whole exome sequen-
cing have not proven to be significantly better than
targeted resequencing as previously expected [29]. This
also supports the usefulness of targeted exome sequen-
cing in RP genetic screening.
Twenty possible causal variants were detected from 10
genes. Of these, 13 variants (65 %) were novel and this
proportion is comparable with recent works reporting
novel allele rates of 62–68 % [25–27, 29]. The consider-
able number of novel variants further emphasises the
use of MPS as a reasonable tool for RP molecular diag-
nosis. The PRPF31 mutation (17.6 %) is most frequently
found in current study, followed by mutations in EYS,
PDE6B, RHO, RP1, and RP2 (11.8 % respectively). PRPF31
(30 %), RHO (20 %), and RP1 (20 %) were frequently af-
fected genes in autosomal dominant RP (adRP), whereas
EYS (40 %) and PDE6B (40 %) were frequently affected
genes for autosomal recessive RP (arRP). Despite the limi-
tation of extending this result to the general distribution
of RP mutations in Koreans, frequently affected genes are
similar to those reported in recent works as well as previ-
ous reports by Hartong et al. [2, 23, 27, 29]. Possible
causal genes responsible for simplex cases had primarily
autosomal recessive inheritance (5 out of 7 cases, 71 %) as
suggested previously [1, 2]. It could not be confirmed
whether causal alleles were de novo because segregation
analysis was not able to be performed in simplex cases.
In X-linked RP, the RPGR gene is thought to be the
most common causal gene, accounting for over 70 % of
cases [30]. Although the RPGR gene was included in the
capture library of the present study, the candidate causal
variant could not be found. ORF15 is a mutation hotspot
of RPGR, where roughly two thirds of disease-causing
mutations are found [30]. This repetitive purine-rich
ORF15 region is rarely covered by next-generation se-
quencing. Therefore, the RPGR mutation could have
been missed and, instead, only the RP2 variants detected.
A missense variant (p.C114R) in family F04 and a trun-
cating variant (p.S187Tfs*31) in family F12 was identi-
fied. The missense variant (p.C114R) was located in the
conserved tubulin binding cofactor C (TBCC) domain
and was evolutionarily conserved. Interestingly, family
F12 showed an autosomal dominant pattern without
male to male transmission. Unlike the expected pattern
of an X-linked disease affecting only males, recent stud-
ies have reported that RP2 and RPGR mutation cause
variable RP phenotypes in heterozygous female pa-
tients.[30–32] Furthermore, it is reported that mutations
in RP2 and RPGR account for 8.5 % of patients with RP
in provisional autosomal dominant families [33].
PRPF31 variants were identified in two families and
one simplex RP patient. One splicing site variation
(c.421-1G > A in family F07) and truncating variant
(p.R354X in family XF3) were known pathogenic vari-
ants [11, 12]. Haploinsufficiency from a null allele ra-
ther than gain of function is assumed to be the major
mechanism of PRPF31 mutation-derived RP [34]. How-
ever, missense variants also have been suggested as
possibly pathogenic in several reports [34–37]. A mis-
sense variant (p.E104K) was also detected in a simplex
RP patient (430) in the current study. This substitution
is located at the highly conserved NOSIK domain and
this sequence is evolutionarily conserved.
An EYS variant was identified in two simplex patients.
The same frameshift insertion variant (p.S1653Kfs*) was
identified in two unrelated patients. As a second candi-
date allele, 439 had a premature truncating variant
(p.E584X) and 440 had a missense variant (p.G2186E).
Nonsense mediated decay from a heterozygous com-
pound truncating mutation is assumed to be a possible
pathogenic mechanism in 439. The missense variant
(p.G2186E) in patient 440 was located in the highly con-
served Laminin G domain. Interestingly, this mutation
was previously reported in a patient with Korean ances-
try [16]. A frameshift variant (p.S1653Kfs*) and missense
variant (p.G2186E) were recurrent in a relatively small
cohort and it is assumed that these could be founder
variants in Koreans. Iwanami et al. suggested that pa-
tients having a homozygous or compound heterozygous
truncating mutation of EYS show a more severe decline
of visual function than patients having only one allele of
the truncating variant [15]. However, both cases (439
and 440) did not show any difference in progression in
the current study independent from number of truncat-
ing variants.
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Table 3 53 RP-related genes selected for targeted resequencing
Gene Inheritance RefSeq Cytogenetic Loci Exon Count Description
ABCA4 AR/AD NM_000350 1p22.1 50 ATP-binding cassette, sub-family A (ABC1), member 4 (ABCA4)
ARL6 AR NM_177976 3q11.2 9 ADP-ribosylation factor-like 6 (ARL6), transcript variant 2
BEST1 AD NM_001139443 11q12.3 9 bestrophin 1 (BEST1), transcript variant 2
C2ORF71 AR NM_001029883 2p23.2 2 chromosome 2 open reading frame 71 (C2orf71)
CA4 AD NM_000717 17q23.1 8 carbonic anhydrase IV (CA4)
CERKL AR NM_201548 2q31.3 13 ceramide kinase-like (CERKL), transcript variant 1
CLRN1 AR NM_001195794 3q25.1 4 clarin 1 (CLRN1), transcript variant 5
CNGA1 AR NM_001142564 4p12 10 cyclic nucleotide-gated channel alpha 1 (CNGA1), transcript
variant 1
CNGB1 AR NM_001297 16q21 33 Homo sapiens cyclic nucleotide-gated channel beta 1 (CNGB1),
transcript variant 1
CRB1 AR NM_201253 1q31.3 12 crumbs homolog 1 (Drosophila) (CRB1), transcript variant 1
CRX AD NM_000554 19q13.33 4 cone-rod homeobox (CRX)
DHDDS AR NM_024887 1p36.11 9 Homo sapiens dehydrodolichyl diphosphate synthase (DHDDS),
transcript variant 2
EYS AR NM_001142800 6q12 43 eyes shut homolog (Drosophila) (EYS), transcript variant 1
FAM161A AR NM_001201543 2p15 7 family with sequence similarity 161, member A (FAM161A),
transcript variant 1
FSCN2 AD NM_001077182 17q25.3 5 fascin homolog 2, actin-bundling protein, retinal
(Strongylocentrotus purpuratus) (FSCN2), transcript variant 2
GUCA1B AD NM_002098 6p21.1 4 guanylate cyclase activator 1B (retina) (GUCA1B)
IDH3B AR NM_006899 20p13 12 isocitrate dehydrogenase 3 (NAD+) beta (IDH3B), nuclear gene
encoding mitochondrial protein, transcript variant 1
IMPDH1 AD NM_000883 7q32.1 17 IMP (inosine 5′-monophosphate) dehydrogenase 1 (IMPDH1),
transcript variant 1
IMPG2 AR NM_016247 3q12.3 19 interphotoreceptor matrix proteoglycan 2 (IMPG2)
KLHL7 AD NM_001031710 7p15.3 11 kelch-like family member 7 (KLHL7), transcript variant 1
LRAT AR NM_004744 4q32.1 3 lecithin retinol acyltransferase (phosphatidylcholine–retinol
O-acyltransferase) (LRAT)
MERTK AR NM_006343 2q13 19 c-mer proto-oncogene tyrosine kinase (MERTK)
NR2E3 AR/AD NM_016346 15q23 8 nuclear receptor subfamily 2, group E, member 3 (NR2E3), transcript
variant 1
NRL AD NM_006177 14q11.2 3 neural retina leucine zipper (NRL)
PDE6A AR NM_000440 5q32 22 phosphodiesterase 6A, cGMP-specific, rod, alpha (PDE6A)
PDE6B AR NM_000283 4p16.3 22 phosphodiesterase 6B, cGMP-specific, rod, beta (PDE6B),
transcript variant 1
PDE6G AR NM_002602 17q25.3 4 phosphodiesterase 6G, cGMP-specific, rod, gamma (PDE6G),
transcript variant 1
PRCD AR NR_033357 17q25.1 5 Homo sapiens progressive rod-cone degeneration (PRCD),
transcript variant 2
PROM1 AR NM_006017 4p15.32 27 prominin 1 (PROM1), transcript variant 1
PRPF3 AD NM_004698 1q21.2-q21.3 16 PRP3 pre-mRNA processing factor 3 homolog (S. cerevisiae) (PRPF3)
PRPF31 AD NM_015629 19q13.42 14 PRP31 pre-mRNA processing factor 31 homolog (S. cerevisiae)
(PRPF31)
PRPF8 AD NM_006445 17p13.3 43 PRP8 pre-mRNA processing factor 8 homolog (S. cerevisiae) (PRPF8)
PRPH2 AD NM_000322 6p21.1 3 peripherin 2 (retinal degeneration, slow) (PRPH2)
PRPH2-
ROM1
digenic NM_000327 11q12.3 3 retinal outer segment membrane protein 1
(ROM1)
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A known pathogenic missense variant (p.H278Y) of
PDE6B was detected in two unrelated patients (436 and
445). A truncating variant (p.W11X) was found in pa-
tient 436 as a second variant and a novel missense
variant (p.I256N) was detected in patient 445. This
missense variant is located in the highly conserved GAF
domain. Loss of function of cGMP phosphoodiesterase
activity is a possible mechanism in these two patients.
Just one possible pathogenic allele was found in the
XF4 family and simplex patients 433, 435 and 450. (Data
not shown in Tables 1 and 2) The identified genes in
these patients have an autosomal recessive inheritance
pattern. Known pathogenic variants (p.C3416G of
USH2A in XF4 and 450, p.Y2935X of EYS in 435) were
found in just one allele. As a second pathogenic canda-
date, missense variants p.T2465S of EYS and p.V2228E
of USH2A were detected and predicted to be patho-
genic in patient 435 and 450, respectively. (Additional
file 1: Table S4) These were relatively common variants
(more than 1 %) in the genomic data of 1000 Asians.
Considering that the counter allele, p.Y2935X and
p.C3416G, is rare and pathogenic, these candidate vari-
ants may also be pathogenic alleles. Regarding other
cases in the current study (XF4 and 433), a second
pathogenic allele could not be identified. Meaningful
second variants may not have been identified because
they were large indels or located in an untranslated re-
gion. Alternatively, detected pathogenic variants might
be accidental carriers and causal variants are located in
other genes. Accidental carrier mutations are increas-
ingly being reported as the use of multigenic screening
with MPS increases [23, 27]. Although the current
study revealed a possible causative variant in half of
cases, obviously a candidate causal allele could not be
found in the other half of patients. Since the target
library was designed, three more causative genes have
been added to the RP gene list. Unknown causal genes
for RP can still exist and including these targets would
increase the detection yield. However, whole exome
sequencing or the use of an extended target library of
over 100 genes has not revealed a higher detection rate
[25, 29, 38]. Unbiased sequencing not only poses an
enormous data processing burden, but also impedes
deep sequencing. Covering the non-coding exons of
target genes and complete coverage of the target may
be better way to increase diagnostic yield rather than
extending the target library. Eisenberg et al. reported
high detection rates using high coverage, copy number
variance (CNV) analysis and sequencing the 5′ UTR
[27]. Xu et al. reported that complete coverage using
Table 3 53 RP-related genes selected for targeted resequencing (Continued)
RBP3 AR NM_002900 10q11.22 4 retinol binding protein 3, interstitial (RBP3)
RDH12 AR NM_152443 14q24.1 9 Homo sapiens retinol dehydrogenase 12 (all-trans/9-cis/11-cis)
(RDH12)
RGR AR/AD NM_002921 10q23.1 7 G protein coupled receptor (RGR), transcript variant 1
RHO AR/AD NM_000539 3q22.1 5 rhodopsin (RHO)
RLBP1 AR NM_000326 15q26.1 9 retinaldehyde-binding protein 1 (RLBP1)
RP1 AR/AD NM_006269 8q12.1 4 retinitis pigmentosa 1 (autosomal dominant) (RP1)
RP2 X-linked NM_006915 Xp11.23 5 retinitis pigmentosa 2 (X-linked recessive) (RP2)
RP9 AD NM_203288 7p14.3 6 retinitis pigmentosa 9 (autosomal dominant) (RP9)
RPE65 AR NM_000329 1p31.3-p31.2 14 retinal pigment epithelium-specific protein 65 kDa (RPE65)
RPGR X-linked NM_001034853 Xp11.4 15 retinitis pigmentosa GTPase regulator (RPGR), transcript variant C
SAG AR NM_000541 2q37.1 16 S-antigen; retina and pineal gland (arrestin) (SAG)
SEMA4A AR/AD NM_001193300 1q22 15 sema domain, immunoglobulin domain (Ig), transmembrane
domain (TM) and short cytoplasmic domain, (semaphorin) 4A
(SEMA4A), transcript variant 2
SNRNP200 AD NM_014014 2q11.2 45 small nuclear ribonucleoprotein 200 kDa (U5) (SNRNP200)
SPATA7 AR NM_018418 14q31.3 12 spermatogenesis-associated 7 (SPATA7), transcript variant 1
TOPORS AD NM_005802 9p21.1 3 topoisomerase I binding, arginine/serine-rich, E3 ubiquitin protein
ligase (TOPORS), transcript variant 1
TTC8 AR NM_144596 14q31.3 15 tetratricopeptide repeat domain 8 (TTC8), transcript variant 1
TULP1 AR NM_003322 6p21.31 15 Tubby-like protein 1 (TULP1)
USH2 /
USH2A
AR NM_206933 1q41 72 Usher syndrome 2A (autosomal recessive, mild) (USH2A), transcript
variant 2
ZNF513 AR NM_144631 2p23.3 4 zinc finger protein 513 (ZNF513), transcript variant 1
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deep sequencing and PCR amplicon for less covered
regions yielded an 82 % detection rate [23]. Although
a ≥ 10X sequencing depth was reached in 96 % of the
sequenced region, 4 % had a less than 10X depth and
1.4 % was not covered (Additional file 1: Table S1).
GC-rich regions or highly repetitive regions are usually
under-captured by MPS. The mutational hotspot,
ORF15 of RPGR, is one of those regions. Complete
coverage assisted by direct sequencing and deep se-
quencing is needed to raise the causative variant de-
tection yield.
Identifying a causal mutation is the starting point of
RP treatment, followed by proper genetic counselling
and prognostic data. For instance, patients can be in-
formed that they have a certain mutation, which puts
them at risk for rapid progression of RP, and aggressive
therapy can be initiated on the basis of confirmative gen-
etic data, although there are limited treatment options
available to help RP patients as of yet. Gene therapy, one
of the possible treatment options for RP, is largely
dependent on genetic data, indicating that identifying
the causal mutation will become an increasingly import-
ant step in RP treatment.
Conclusion
Using the targeted re-sequencing of known genes for
RP, pathogenic and possibly pathogenic variants were
identified in more than the half of patients and
families. This strategy will become an increasingly effi-




Sixty-two Korean patients with RP were selected for the
RP cohort. This cohort consisted of 46 patients from 18
families and 16 patients with simplex RP. All the pa-
tients had nonsyndromic RP. Comprehensive ocular ex-
aminations, including visual acuity assessment, slit-lamp
examination, fundus examination, electroretinograms,
Goldmann Perimetry (Haag-Streit, Bern, Switzerland)
and optical coherence tomography (Carl Zeiss Meditec
Inc., Dublin, CA, USA) were used for clinical diagnosis.
RP was diagnosed when the patients had the typical
retinal appearance of RP and had attenuated or abol-
ished rod and cone signal on electroretinography. Bony
spicule-like pigment deposits, retinal vessel attenuation
and optic disc pallor were included in the characterisa-
tion of typical retinal features of RP. It was assumed
that the mode of inheritance was autosomal dominant
when a patient appeared in every generation of the pedi-
gree, and when affected fathers and mothers transmitted
Fig. 1 Schematic workflow of the diagnostic application of targeted
exome sequencing in familial and simplex retinitis pigmentosa. 62
cases consisting of 46 patients in 18 families and 16 cases in simplex
families were recruited, and targeted re-sequencing was performed for
53 RP-related genes. Candidate variants were identified by filtering
based on variant quality > 20 and minor allele frequency < 0.01 from
1000 Genome Project (www.1000genomes.org), Exome Variant Server
(evs.gs.washington.edu) and our in-house DB consisting of 192 Korean
exomes. The variants were finally confirmed by a cosegregation test if
familiar cases, in silico tools and Sanger sequencing
Table 4 Classification of candidate variants in this study
Category Explanation
Class I Previously reported pathogenic variants
Class II Single Nucleotide Variants (SNVs) predicted to cause serious
protein deformity by using in silico analysis
Stopgain, and frameshift mutations
Class III Mutations causing only protein change
Class IV Other mutations
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the phenotype to both sons and daughters. Autosomal
recessive patterns were suspected when a phenotype
appeared in the male and female progeny of unaffected
parents. X-linked recessive inheritance was suspected
when affected males passed the condition on to all of their
daughters, but to none of their sons, and female patients
married to unaffected males passed the condition on to
half of their sons and daughters. Written informed
consent was obtained from all patients before they were
enrolled in the study. This study followed the tenets of the
declaration of Helsinki (Edinburgh, 2000) and was
approved by the Institutional Review Board of Seoul
National University Hospital.
Targeted exome sequencing of RP-related genes
Customised baits were designed to capture all exons of
the 53 genes known to be associated with RP at the
time of panel design. (Table 3, Roche NimbleGen Inc,
Madison, WI). Genomic DNA from 62 patients in total
was extracted from peripheral blood as described pre-
viously [39] and was sequenced using the Genome
Analyzer II. Sequencing reads were aligned to the
UCSC hg19 reference genome using BWA-0.6.1 with
default settings. Duplications were removed via Picard
v1.93, and local realignment was done by GATK v2.4-7.
Variants were identified by the Unified Genotyper from
GATK for the SNVs and indels. ANNOVAR was used to
annotate the variants. Coverage of TES data was calcu-
lated by the ‘Depth of Coverage’ module from GATK.
Sanger sequencing for candidate variants was performed
using specific primers for each exon as demonstrated.
Prioritization of variants
A flowchart for candidate causal variant detection is
shown in Fig. 1. Exonic and splicing variants were first
selected if they had an allele frequency below 1 % re-
ported in the NHLBI-ESP 6500 (evs.gs.washington.edu),
1000 Genome Project (www.1000genomes.org), and an
in-house database with exomes of 192 Korean individ-
uals. Variants with a quality score below 20 were ex-
cluded. Candidate variants were confirmed by Sanger
sequencing and co-segregation analysis was performed
in cases of familial RP. The potential pathogenicity of
variants was categorised into four classes (Table 4).
Briefly, Class I included pathogenic variants previously
known to cause RP, and Class II variants were expected
to cause severe damage to protein structure via frame-
shift, nonsense, and missense variants, which were likely
to cause severe functional change via Polyphen 2 [40],
SIFT [41], and MutPred [42]. Class III included variants
least likely to be causative and consisted of missense
variations that were predicted to be benign or tolerable.
All other types of variants were categorised as Class IV.
Novel nonsynonymous variants were assumed to be
possibly pathogenic if the variant was predicted to be
pathogenic by at least two of the three methods. Both
probably and possibly damaging mutations were classi-
fied as suspected pathogenic variants by Polyphen2.
With regard to SIFT, damaging mutations were classified
as pathogenic. For Mutpred, a general score higher than
0.5 was categorised as possibly pathogenic.
Additional files
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In silico prediction for nonsysnonymous variants. Figure S1. Pedigrees of 10
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